GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » Shiller PE Ratio

Bellicum Pharmaceuticals (FRA:BPXA) Shiller PE Ratio : (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bellicum Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Bellicum Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Shiller PE Ratio Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bellicum Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellicum Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Shiller PE Ratio falls into.



Bellicum Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Bellicum Pharmaceuticals's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Bellicum Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.019/129.8595*129.8595
=-0.019

Current CPI (Sep. 2023) = 129.8595.

Bellicum Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -2.148 98.326 -2.837
201403 -2.082 99.695 -2.712
201406 -2.880 100.560 -3.719
201409 -1.385 100.428 -1.791
201412 -15.401 99.070 -20.187
201503 -2.772 99.621 -3.613
201506 -3.564 100.684 -4.597
201509 -4.544 100.392 -5.878
201512 -5.783 99.792 -7.525
201603 -5.029 100.470 -6.500
201606 -5.429 101.688 -6.933
201609 -5.881 101.861 -7.498
201612 -7.015 101.863 -8.943
201703 -7.480 102.862 -9.443
201706 -6.586 103.349 -8.275
201709 -5.957 104.136 -7.429
201712 -5.492 104.011 -6.857
201803 -5.515 105.290 -6.802
201806 -5.136 106.317 -6.273
201809 -4.714 106.507 -5.748
201812 -5.538 105.998 -6.785
201903 -4.903 107.251 -5.937
201906 -5.177 108.070 -6.221
201909 -6.165 108.329 -7.390
201912 -5.238 108.420 -6.274
202003 0.986 108.902 1.176
202006 -7.592 108.767 -9.064
202009 -0.153 109.815 -0.181
202012 0.806 109.897 0.952
202103 -0.941 111.754 -1.093
202106 -0.183 114.631 -0.207
202109 0.060 115.734 0.067
202112 0.097 117.630 0.107
202203 -0.227 121.301 -0.243
202206 -0.123 125.017 -0.128
202209 -0.232 125.227 -0.241
202212 -0.189 125.222 -0.196
202303 -0.243 127.348 -0.248
202306 -0.222 128.729 -0.224
202309 -0.019 129.860 -0.019

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bellicum Pharmaceuticals  (FRA:BPXA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Bellicum Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (FRA:BPXA) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (FRA:BPXA) Headlines

No Headlines